Integrative transcriptomic and single-nucleus analyses identify microbiota–metabolite-associated immune signatures of fibrosis severity in MASLD

OBJECTIVE: To identify microbiota-metabolite-associated immune features associated with fibrosis severity and evaluate their cross-cohort expression, discrimination and cellular context in human liver. METHODS: Discovery used 206 NAFLD cases from GSE135251, comparing F0-F2 with F3-F4. Human gutMGene host genes were intersected with ImmPort immune genes, followed by transcriptome-wide FDR filtering, LASSO and balanced Random Forest selection. Complete-pipeline five-fold cross-validation assessed internal performance. Fixed features and coefficients were evaluated in GSE130970, including age- and sex-adjusted sensitivity analyses. GSE244832 provided single-nucleus localization and descriptive CellChat context. RESULTS: Discovery identified 721 global differentially expressed genes and 23 candidates from a 72-gene biological prior. Eight features were selected: CCL2, MYC, CASP1, CAT, DEFB1, NLRP6, HMOX1 and SMURF2. Apparent discovery AUC was 0.859, full-pipeline out-of-fold AUC was 0.805, and fixed-processing external AUC was 0.808 (95% CI, 0.670-0.946). Five features showed concordant external differences after multiple-testing correction; four remained significant after age-sex adjustment. SMURF2 showed an opposite association. The fixed score remained associated with F3-F4 after adjustment (OR 3.09; 95% CI, 1.49-6.42). CASP1/HMOX1 localized predominantly to Macrophage/Kupffer cells and CCL2 to Fibroblast/Stellate cells; NLRP6 was sparsely detected. Donor-level differences were not significant after correction. CONCLUSIONS: The exploratory signature showed retrospective cross-cohort discrimination with heterogeneous gene-level support. Cellular localization and inferred communication provide biological context. Limited clinical covariates, external sample size, measurement differences and probability calibration restrict clinical interpretation. Prospective and experimental validation are required.

Authors

Institutions

Publication Details

Journal
PLoS ONE
Published
2026-11-16
DOI
https://doi.org/10.1371/journal.pone.0362860
Primary Topic
Liver Disease Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Integrative transcriptomic and single-nucleus analyses identify microbiota–metabolite-associated immune signatures of fibrosis severity in MASLD

Feihu Zhang, Tejin Ba, Qianyu Bi, Zhiyun Liu et al.
3 links
PLoS ONE
Liver Disease Diagnosis and Treatment
article

Integrative transcriptomic and single-nucleus analyses identify microbiota–metabolite-associated immune signatures of fibrosis severity in MASLD

Feihu Zhang, Tejin Ba, Qianyu Bi, Zhiyun Liu, Li Kong, Chun-lei Liu, Jing Feng, Wen-qiao Lu, Lin Wang, Jie Gao
article en

Abstract

OBJECTIVE: To identify microbiota-metabolite-associated immune features associated with fibrosis severity and evaluate their cross-cohort expression, discrimination and cellular context in human liver. METHODS: Discovery used 206 NAFLD cases from GSE135251, comparing F0-F2 with F3-F4. Human gutMGene host genes were intersected with ImmPort immune genes, followed by transcriptome-wide FDR filtering, LASSO and balanced Random Forest selection. Complete-pipeline five-fold cross-validation assessed internal performance. Fixed features and coefficients were evaluated in GSE130970, including age- and sex-adjusted sensitivity analyses. GSE244832 provided single-nucleus localization and descriptive CellChat context. RESULTS: Discovery identified 721 global differentially expressed genes and 23 candidates from a 72-gene biological prior. Eight features were selected: CCL2, MYC, CASP1, CAT, DEFB1, NLRP6, HMOX1 and SMURF2. Apparent discovery AUC was 0.859, full-pipeline out-of-fold AUC was 0.805, and fixed-processing external AUC was 0.808 (95% CI, 0.670-0.946). Five features showed concordant external differences after multiple-testing correction; four remained significant after age-sex adjustment. SMURF2 showed an opposite association. The fixed score remained associated with F3-F4 after adjustment (OR 3.09; 95% CI, 1.49-6.42). CASP1/HMOX1 localized predominantly to Macrophage/Kupffer cells and CCL2 to Fibroblast/Stellate cells; NLRP6 was sparsely detected. Donor-level differences were not significant after correction. CONCLUSIONS: The exploratory signature showed retrospective cross-cohort discrimination with heterogeneous gene-level support. Cellular localization and inferred communication provide biological context. Limited clinical covariates, external sample size, measurement differences and probability calibration restrict clinical interpretation. Prospective and experimental validation are required.

PLoS ONEVol. 21(11)
Shandong University of Traditional Chinese Medicine (CN), Inner Mongolia International Mongolian Hospital (CN), Affiliated Hospital of Shandong University of Traditional Chinese Medicine (CN)
Good health and well-being
Liver Disease Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon